IXICO PLC (LON:IXI) has expanded its contract with a biopharmaceutical company, taking the total value to €1.3mln.
The AIM-listed data science company said the change order extended the contract, which focuses on Alzheimer’s disease, from an end date of September 2020 to May 2021, as well as the addition of new clinical sites.
WATCH: IXICO full year performance expected to be 'ahead of market expectations'
The original value of the contract was €0.8mln, with the latest change order representing a 65% increase.
Giulio Cerroni, chief executive of IXICO, said: "We are delighted to announce a further extension and expansion of this project. This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes."